Dimensional Fund Advisors LP Raises Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Dimensional Fund Advisors LP boosted its holdings in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 23.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 977,470 shares of the company's stock after buying an additional 183,844 shares during the quarter. Dimensional Fund Advisors LP owned 1.16% of Atea Pharmaceuticals worth $3,274,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of AVIR. Intech Investment Management LLC increased its holdings in shares of Atea Pharmaceuticals by 236.0% during the 4th quarter. Intech Investment Management LLC now owns 35,989 shares of the company's stock valued at $121,000 after purchasing an additional 25,278 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Atea Pharmaceuticals by 27.8% during the 4th quarter. Wells Fargo & Company MN now owns 45,391 shares of the company's stock valued at $152,000 after purchasing an additional 9,865 shares in the last quarter. HighTower Advisors LLC purchased a new position in shares of Atea Pharmaceuticals during the 4th quarter valued at approximately $168,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Atea Pharmaceuticals by 72.9% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 76,352 shares of the company's stock valued at $256,000 after purchasing an additional 32,195 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Atea Pharmaceuticals during the 4th quarter valued at approximately $260,000. 86.67% of the stock is owned by hedge funds and other institutional investors.

Atea Pharmaceuticals Trading Up 2.6%

AVIR traded up $0.07 on Monday, hitting $2.81. 353,148 shares of the company's stock were exchanged, compared to its average volume of 307,046. Atea Pharmaceuticals, Inc. has a fifty-two week low of $2.46 and a fifty-two week high of $4.15. The firm has a 50-day moving average price of $2.90 and a 200-day moving average price of $3.09. The stock has a market cap of $240.48 million, a price-to-earnings ratio of -1.36 and a beta of 0.17.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.16. On average, equities analysts predict that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Analysts Set New Price Targets

AVIR has been the topic of a number of research analyst reports. Morgan Stanley dropped their price target on shares of Atea Pharmaceuticals from $6.20 to $6.00 and set an "equal weight" rating on the stock in a research note on Friday, April 11th. William Blair reissued an "outperform" rating on shares of Atea Pharmaceuticals in a research note on Friday, March 7th.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.